<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047406</url>
  </required_header>
  <id_info>
    <org_study_id>RHDIRB2020110301REC 46</org_study_id>
    <nct_id>NCT05047406</nct_id>
  </id_info>
  <brief_title>Bacillus Clausii in Liver Transplantation</brief_title>
  <official_title>Effect of Probiotic Administration on Infection Incidence Rate in Living Donor Liver Transplantation Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, controlled study of the safety and efficacy of using Bacillus&#xD;
      clausii probiotic oral preparation to decrease the incidence of infection during the first 30&#xD;
      days after living donor liver transplantation surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients planned for living donor liver transplantation would be randomized to either&#xD;
      intervention or control group 2 weeks before surgery. Intervention group shall receive&#xD;
      Bacillus clausii probiotics for 2 weeks. patients in both groups would be followed-up for&#xD;
      adverse events and signs and symptoms of infection up to 30 days postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, controlled, open-label, parallel, single-center study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>infection and mortality rates</measure>
    <time_frame>up to 30 days post-operatively</time_frame>
    <description>the occurrence of post-operative bacterial infection and mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>type of isolated bacteria</measure>
    <time_frame>up to 30 days post-operatively</time_frame>
    <description>culture and sensitivity results of isolated bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total hospital stay</measure>
    <time_frame>up to 30 days post-operatively</time_frame>
    <description>total length of hospital stay defined as the day of surgery and day of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total ICU stay</measure>
    <time_frame>up to 30 days post-operatively</time_frame>
    <description>total length of ICU stay defined as the day of surgery and day of regular ward transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Probiotic related adverse events</measure>
    <time_frame>starting 2 weeks before surgery and up to 30 days post-operatively</time_frame>
    <description>incidence of adverse events and/or side effects related to probiotics use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic therapy</measure>
    <time_frame>up to 30 days post-operatively</time_frame>
    <description>duration of antibiotic therapy after exclusion of period of antibiotic prophylaxis without signs of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessment</measure>
    <time_frame>at baseline, on day 15 before surgery, and at 30 days post-transplantation</time_frame>
    <description>quality of life assessment using liver disease symptom index 2.0 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase level (AST)</measure>
    <time_frame>at baseline before probiotic administration and at 30 days post-transplantation</time_frame>
    <description>serum aspartate aminotransferase level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase level (ALT)</measure>
    <time_frame>at baseline before probiotic administration and at 30 days post-transplantation</time_frame>
    <description>serum alanine aminotransferase level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>international normalized ratio</measure>
    <time_frame>at baseline before probiotic administration and at 30 days post-transplantation</time_frame>
    <description>ratio between patient's prothrombin time and that of health laboratory standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin level</measure>
    <time_frame>at baseline before probiotic administration and at 30 days post-transplantation</time_frame>
    <description>total serum bilirubin level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Transplantation Infection</condition>
  <condition>Liver Grafting</condition>
  <condition>Hepatic Transplantation</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 oral mini-bottles daily of Bacillus clausii probiotic liquid containing 2 billion spores/bottle for 2 weeks before living donor liver transplantation surgery In addition, patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (No Probiotic)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bacillus clausii Probiotic liquid</intervention_name>
    <description>mini bottles for oral administration containing 2 million spores of Bacillus clausii</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Enterogermina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18 - 65 years.&#xD;
&#xD;
          -  Patients suffering from end stage liver disease (ESLD) with any etiology listed on&#xD;
             waiting list and accepting to volunteer in the study with the informed consent.&#xD;
&#xD;
          -  Patients not suffering from any active infection at the start of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with poorly controlled autoimmune disease on immunosuppression before&#xD;
             transplantation.&#xD;
&#xD;
          -  Patients who undergo combined kidney-liver transplantation.&#xD;
&#xD;
          -  Patients with severe renal insufficiency (creatinine clearance &lt;50 ml/min).&#xD;
&#xD;
          -  Patients with intestinal obstruction (ileus).&#xD;
&#xD;
          -  Patients with cerebral disorders with danger of aspiration.&#xD;
&#xD;
          -  Patients with roux en Y-anastomosis.&#xD;
&#xD;
          -  Patients with cystic fibrosis.&#xD;
&#xD;
          -  Retransplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rana Sayed, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Pharmacy, Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rana Sayed, PhD</last_name>
    <phone>01208164247</phone>
    <email>ranasayed@pharma.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams Center for Organ Transplantation, Ain Shams Specialized Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Nabet, Msc.</last_name>
      <phone>01001841043</phone>
      <email>dina_nabet@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 11, 2021</last_update_submitted>
  <last_update_submitted_qc>September 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dina Ezzeldin Nabet</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>transplantation</keyword>
  <keyword>infection</keyword>
  <keyword>probiotics</keyword>
  <keyword>Bacillus clausii</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

